Profile data is unavailable for this security.
About the company
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.
- Revenue in USD (TTM)5.49m
- Net income in USD-50.73m
- Incorporated2014
- Employees53.00
- LocationCue Biopharma Inc40 Guest StreetBOSTON 02135United StatesUSA
- Phone+1 (617) 949-2680
- Fax+1 (302) 655-5049
- Websitehttps://www.cuebiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elutia Inc | 24.75m | -41.25m | 69.53m | 54.00 | -- | -- | -- | 2.81 | -2.20 | -2.08 | 1.35 | -1.66 | 0.4408 | 1.97 | 4.90 | 458,240.80 | -73.48 | -42.93 | -309.94 | -79.34 | 44.67 | 43.32 | -166.70 | -64.16 | 0.6367 | -3.54 | -- | -- | -49.69 | -8.71 | -25.39 | -- | 12.74 | -- |
| Beyondspring Inc | 1.55m | -27.51m | 70.06m | 67.00 | -- | -- | -- | 45.20 | -0.7043 | -0.7043 | 0.0397 | -0.4637 | 0.0321 | -- | -- | 21,232.88 | -60.79 | -91.82 | -81.96 | -118.82 | -- | -- | -1,895.29 | -9,233.73 | -- | -- | -- | -- | 0.00 | -- | 48.15 | -- | -14.86 | -- |
| Carisma Therapeutics Inc | 10.63m | -73.50m | 70.62m | 17.00 | -- | 1.48 | -- | 6.64 | -3.70 | -3.70 | 0.411 | 1.15 | 0.0694 | -- | -- | 625,294.10 | -47.96 | -25.47 | -56.78 | -27.87 | -- | -- | -691.39 | -236.32 | -- | -- | 0.0211 | -- | 50.69 | 148.16 | -5,817.86 | -- | -- | -- |
| Champions Oncology Inc | 49.22m | -9.73m | 71.03m | 230.00 | -- | -- | -- | 1.44 | -0.7183 | -0.7183 | 3.64 | -0.1514 | 1.56 | -- | 6.17 | 214,017.40 | -30.91 | -5.40 | -96.45 | -11.88 | 40.09 | 47.96 | -19.76 | -3.09 | -- | -- | -- | -- | 9.69 | 21.63 | -1,073.54 | -- | 18.50 | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -27.03m | 72.09m | 28.00 | -- | 1.86 | -- | -- | -0.5642 | -0.5642 | 0.00 | 0.7889 | 0.00 | -- | -- | 0.00 | -47.51 | -38.31 | -56.21 | -43.34 | -- | -- | -- | -- | -- | -6.33 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
| vTv Therapeutics Inc | 0.00 | -20.25m | 72.64m | 16.00 | -- | -- | -- | -- | -9.79 | -9.79 | 0.00 | -9.27 | 0.00 | -- | -- | 0.00 | -117.34 | -111.84 | -1,613.30 | -- | -- | -- | -- | -680.94 | -- | -- | -- | -- | -100.00 | -- | -5.67 | -- | -- | -- |
| Cue Biopharma Inc | 5.49m | -50.73m | 72.72m | 53.00 | -- | 1.90 | -- | 13.25 | -1.11 | -1.11 | 0.12 | 0.7855 | 0.0719 | -- | 6.26 | 103,584.90 | -66.40 | -57.45 | -81.71 | -68.41 | -- | -- | -924.10 | -810.87 | -- | -- | 0.1804 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
| AN2 Therapeutics Inc | 0.00 | -64.73m | 73.53m | 41.00 | -- | 0.5891 | -- | -- | -2.82 | -2.82 | 0.00 | 4.19 | 0.00 | -- | -- | 0.00 | -53.65 | -- | -58.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
| Cognition Therapeutics Inc | 0.00 | -25.79m | 73.71m | 25.00 | -- | 2.48 | -- | -- | -0.8564 | -0.8564 | 0.00 | 0.7609 | 0.00 | -- | -- | 0.00 | -60.26 | -- | -76.27 | -- | -- | -- | -- | -- | -- | -1,878.67 | 0.00 | -- | -- | -- | -20.52 | -- | -- | -- |
| Tempest Therapeutics Inc | 0.00 | -29.49m | 74.34m | 17.00 | -- | 2.76 | -- | -- | -1.96 | -1.96 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -60.38 | -57.10 | -72.81 | -71.20 | -- | -- | -- | -- | -- | -87.30 | 0.2827 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
| Medicinova Inc | 1.00m | -8.57m | 74.55m | 13.00 | -- | 1.20 | -- | 74.55 | -0.1748 | -0.1748 | 0.0204 | 1.27 | 0.0142 | -- | -- | 76,923.08 | -12.21 | -15.36 | -12.80 | -15.90 | -- | -- | -857.15 | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
| Bakhu Holdings Corp | 0.00 | -1.92m | 75.33m | 2.00 | -- | -- | -- | -- | -0.0064 | -0.0064 | 0.00 | -0.0325 | 0.00 | -- | -- | 0.00 | -281.75 | -4,391.82 | -- | -- | -- | -- | -- | -- | -- | -8.39 | -- | -- | -- | -- | 33.37 | -- | -- | -- |
| Provectus Biopharmaceuticals Inc | 557.71k | -3.10m | 75.47m | 4.00 | -- | -- | -- | 135.32 | -0.0074 | -0.0074 | 0.0013 | -0.0181 | 0.32 | -- | 1,282.09 | 139,427.50 | -177.95 | -276.33 | -- | -- | -- | -- | -556.16 | -1,667.76 | -- | -13.22 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
| Assertio Holdings Inc | 152.07m | -331.94m | 75.59m | 53.00 | -- | 0.5458 | -- | 0.4971 | -3.97 | -3.97 | 2.04 | 1.46 | 0.4343 | 1.04 | 3.27 | 2,869,227.00 | -94.80 | -21.51 | -129.77 | -32.05 | 82.36 | 88.68 | -218.28 | -62.10 | 1.43 | -- | 0.2182 | -- | -2.67 | -13.38 | -402.80 | -- | -28.25 | -- |
| LAVA Therapeutics NV | 6.77m | -41.97m | 75.98m | 37.00 | -- | 1.48 | -- | 11.22 | -1.58 | -1.58 | 0.2532 | 1.95 | 0.0552 | -- | 2.87 | 182,946.00 | -34.25 | -- | -40.31 | -- | 48.56 | -- | -620.09 | -- | -- | -- | 0.1098 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
| Celularity Inc | 14.79m | -181.41m | 76.24m | 225.00 | -- | 2.24 | -- | 5.16 | -10.51 | -10.51 | 0.8376 | 1.56 | 0.0498 | 2.29 | 2.03 | 65,724.45 | -61.05 | -- | -82.37 | -- | 21.19 | -- | -1,226.72 | -- | 0.1366 | 18.40 | 0.5365 | -- | -15.75 | -- | 114.18 | -- | -- | -- |
Data as of Apr 17 2024. Currency figures normalised to Cue Biopharma Inc's reporting currency: US Dollar USD
27.76%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Bleichroeder LPas of 27 Feb 2024 | 2.76m | 6.11% |
| Slate Path Capital LPas of 31 Dec 2023 | 2.40m | 5.32% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.17m | 4.81% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.06m | 4.57% |
| Geode Capital Management LLCas of 31 Dec 2023 | 813.29k | 1.80% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 683.70k | 1.52% |
| Robertson Stephens Wealth Management LLC (Invt Mgmt)as of 31 Dec 2023 | 478.50k | 1.06% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 457.99k | 1.02% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 358.27k | 0.79% |
| Monaco Asset Management SAMas of 31 Dec 2023 | 342.24k | 0.76% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
